Kanjinti vs herceptin

CONCLUSIONS Treatment with KANJINTI proved to be cost-effective and savings generated from patients switching from Herceptin to KANJINTI could be reinvested to

KANJINTI safely and effectively. See full prescribing information for KANJINTI. KANJINTI (trastuzumab-anns) for injection, for intravenous use Initial U.S. Approval: 2024 . KANJINTI (trastuzumab-anns) is biosimilar to HERCEPTIN (trastuzumab) WARNING: CARDIOMYOPATHY, INFUSION REACTIONS, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY

Kanjinti is a biosimilar version of trastuzumab (reference product, Herceptin, Roche, Inc.) developed by the partnership of Amgen and Allergan.

KANJINTI is a biosimilar to the cancer drug Herceptin and is FDA-approved for the same uses. KANJINTI has been tested worldwide and has been proven to have similar side effects as Herceptin . 1,5

Kanjinti (trastuzumab-anns) is biosimilar to Herceptin (trastuzumab). Kanjinti has been shown to be similar to Herceptin in the way in which

label and package insert for the 150 mg presentation. The Product Monograph for Kanjinti, as is found in the Product Monograph for Herceptin.

preparation of KANJINTI, refer to the package insert or call Herceptin (trastuzumab) Prescribing Information [revised 2024], Genentech.

1. INDICATIONS. Indications have been granted on the basis of similarity between KANJINTI and the reference biologic drug HERCEPTIN.

vial; added Herceptin biosimilar, Kanjinti; Herceptin product availability for multi-dose vial corrected from 420 mg to 440 mg; references updated; newly